Clinical Trials in Fayetteville, Georgia
27 recruiting
Showing 1–20 of 26 trials
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled183 locationsNCT07190209
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Grade 2 MeningiomaIntracranial Meningioma
NRG Oncology163 enrolled214 locationsNCT03180268
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1238 locationsNCT05879926
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Immunoglobulin G4-Related Disease
Sanofi124 enrolled68 locationsNCT07190196
Recruiting
Phase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Asthma
AstraZeneca440 enrolled135 locationsNCT06307665
Recruiting
Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Heart FailureHeart Failure With Reduced Ejection Fraction
Cytokinetics1,800 enrolled185 locationsNCT06736574
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi144 enrolled46 locationsNCT07225569
Recruiting
Phase 2
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Hypertension
Novartis Pharmaceuticals380 enrolled84 locationsNCT06857955
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathic pain
Vertex Pharmaceuticals Incorporated734 enrolled65 locationsNCT07231419
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
COPD Acute Exacerbation
Connect Biopharm LLC160 enrolled51 locationsNCT06940154
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Asthma Acute
Connect Biopharm LLC160 enrolled52 locationsNCT06940141
Recruiting
Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
NRG Oncology1,670 enrolled832 locationsNCT04852887
Recruiting
Phase 2Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Type II Diabetes Mellitus
Corxel Pharmaceuticals240 enrolled46 locationsNCT07340320
Recruiting
Not Applicable
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Metabolic SyndromeDiabetes Mellitus, Type 2Prediabetes
Cleerly, Inc.7,500 enrolled123 locationsNCT06112418
Recruiting
Phase 2
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated45 enrolled35 locationsNCT06794996
Recruiting
Phase 4
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
ModernaTX, Inc.30,000 enrolled150 locationsNCT07266558